

Evaluation of dyssynchrony: other techniques

Foley , Paul / Leyva, Francisco

Introduction

According to the currently accepted paradigm underpinning cardiac resynchronization therapy (CRT), cardiac dyssynchrony contributes to the syndrome of heart failure and its correction leads to a clinical benefit. The first testament to this paradigm was provided by Cazeau et al, who in 1994 reported on the dramatic clinical improvement of a 54 year old man who was treated with four-chamber pacing. (1) In an acute haemodynamic study, Leclercq et al subsequently showed that temporary cardiac resynchronisation therapy (CRT) using biventricular pacing led to an increase in left ventricular (LV) output and to a decrease in pulmonary capillary wedge pressure. (2) Reporting on 27 patients with end-stage heart failure, Auricchio et al showed that CRT led to an increase in aortic pulse pressure and LV dP/dt, which reversed immediately after pacing was withdrawn. (3) The Multisite Stimulation in Cardiomyopathies (MUSTIC) study, a single-blind, cross over study of 67 patients, showed that CRT dramatically reduced heart failure hospitalizations and improved NYHA class, as well as quality of life, exercise distance and peak oxygen uptake. (4) The major outcome trial of CRT-pacing (CRT-P), the Cardiac Resynchronization in Heart Failure (CARE-HF) study, showed that this therapy led to a 36% relative reduction in total mortality. (5) The Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) study showed that addition of a cardioverter defibrillator to CRT-P (CRT-D) also led to a mortality benefit. (6)

Several mechanisms have hitherto been offered as possible explanations for the beneficial effects of CRT. The diastolic ventricular interaction, which is demonstrable in patients with heart failure, (7) is relieved by both biventricular and LV pacing. (8) In addition, CRT reduces functional mitral regurgitation, acutely as well as in the long term. (9-11) The roles of blood flow, (12) heart failure aetiology, (13) myocardial viability (14), location of myocardial scarring, (15) and atrial rhythm (16,17) have also been explored. The most intuitive mechanism by which CRT confers a benefit, however, is through correction of dyssynchrony. Whilst echocardiography is the most widely studied imaging modality in relation to the assessment of cardiac dyssynchrony, other techniques are emerging. This review focuses on the assessment of cardiac dyssynchrony using techniques other than echocardiography.

Cardiac Resynchronization Therapy Symposium

Definition of response to CRT

For a test to be clinically meaningful, it must prove its value when evaluated against clinically meaningful parameters, such as symptoms, morbidity and mortality. Because mortality is not always a practicable outcome measure in studies other than large outcome trials, surrogate measures, such as reverse LV remodelling, have found popularity in smaller studies.

To compound the issue of what constitutes a response to a given treatment, a symptomatic is not necessarily associated with a survival benefit. At the extremes, chemotherapy for the treatment of cancer is intended for a survival benefit, but it rarely carries a symptomatic benefit. On the other hand, palliative treatments usually provide symptom relief, but not a survival advantage. In this respect, data from the CARE-HF study suggests that all patients treated with CRT improve relative to those treated with medical therapy alone. (18) On the other hand, other studies have shown that there is a discordance between benefit in terms of symptoms and of surrogate measures of a survival benefit, such as reverse LV remodeling. (19) It is important, therefore, to qualify whether 'responder rate' relates to a survival benefit or a symptomatic benefit, or both. This issue of definition of response applies to most studies of CRT.

As a further limitation, the term 'responder' does not incorporate a measure of the degree with which a treatment prevents deterioration, unless it is compared with placebo. After publication of clinical guidelines, however, CRT cannot be compared to placebo. For this reason, the responder rate quoted in studies other than the CARE-HF and the COMPANION study do not, therefore, reflect the effects of CRT in preventing clinical deterioration, as would be expected from the natural history of heart failure. This is an important factor to take into account in interpreting the findings of CRT studies.

Echocardiography

Echocardiographic studies of the response to CRT have focused on surrogate measures of mortality, the most popular of which is reverse LV remodelling. Several groups have employed tissue Doppler imaging (TDI)-derived measures of the temporal dispersion of the time-to-peak velocity of myocardial segments as a predictor of response to CRT. (20-23) Together, these studies have supported the notion that demonstration of cardiac dyssynchrony prior to implantation is a requirement for a benefit from CRT. (24, 25)

The Predictors of Response to CRT (PROSPECT) study was the first multicentre study to evaluate echocardiography as a predictor of response to CRT. (26) Although concerns have been raised

Cardiac Resynchronization Therapy Symposium

about the quality of data acquisition, data collection and study design, (27) the authors of the original publication concluded that no single echocardiographic measure could be recommended in the selection of patients for CRT. On this basis, the American Society of Echocardiography has recommended that echocardiographic measures of dyssynchrony should not be used in selecting patients for CRT. (28) Apart from the United Kingdom National Institute of Clinical Excellence, no clinical guideline group has adopted echocardiography in selecting patients for CRT.

The PROSPECT study has stimulated a recapitulation of the role of echocardiographic measures of dyssynchrony in selecting patients for CRT. In a recent review, Marwick referred to the numerous dyssynchrony measures as the tower of Babel. (29) In his review, Marwick alludes to the limitations of TDI in measuring dyssynchrony. He also refers to the clinical impracticality of the numerous techniques used to quantify dyssynchrony. In this regard, some anomalies of definition have arisen. Various groups have shown, for example, that even healthy controls have dyssynchrony. (30-33) Others have shown that some patients with heart failure and broad QRS do not satisfy the echocardiographic criteria for dyssynchrony. (34) Whilst echocardiography boasts of exquisitely high temporal resolution, this may actually work against it, as it also increases 'noise'. (35) After a decade of research, there is no consensus with regard to the role of echocardiography in the quantification of dyssynchrony for the purposes of selecting patients for CRT.

Nuclear imaging

Myocardial scintigraphy allows measurement of ventricular volumes, myocardial perfusion as well as myocardial motion. To evaluate the prognostic value of interventricular and intraventricular dyssynchrony, Fauchier et al studied 103 patients with non-ischaemic cardiomyopathy, 25% of whom had a left bundle branch block (LBBB). (36) Fourier phase analysis of equilibrium radionuclide angiographic data was performed for both right and left ventricles. (**Fig.1**) The difference between the mean phase of left and right ventricles was taken as a measure of interventricular dyssynchrony, whereas the standard deviations of the mean phase in each ventricle was taken as a measure of intraventricular dyssynchrony. The authors found that over a mean follow-up of 27 months, the standard deviation of the LV and right ventricular mean phase (intraventricular dyssynchrony) predicted cardiac events. Among 13 potential predictors of cardiac events on univariate analyses, a high standard deviation of the LV mean phase (intraventricular dyssynchrony) and a high pulmonary capillary wedge pressure emerged as independent predictors of cardiac events in multivariate analyses.

Cardiac Resynchronization Therapy Symposium

Figure 1




Figure 1. Phase analysis of radionuclide ventriculography data. The images show the ventriculograms obtained from the left and right ventricles. (a) shows a mean phase of 384 ms for the left ventricle and 346 ms for the right ventricle, which amounts to a phase difference of 38 ms; (b) shows a mean phase of 230 ms for the left ventricle and 212 ms for the right ventricle, which amounts to a mean difference of 18 ms. Reproduced with permission from Fauchier et al. (36)

Henneman et al used phase analysis of gated myocardial perfusion single photon computed tomography (SPECT) to assess intraventricular dyssynchrony. Four indices of dyssynchrony derived from the phase analysis were found to correlate well with septal-to-posterior wall motion delay on TDI. (37) In another study of 42 patients undergoing CRT, the same group found that the standard deviation of a phase angle of 42° on SPECT was the best predictor of improvement in NYHA class (by ≥ 1) at six months (area under the receiver operator characteristic curve of 0.81). (38) Other groups have found that SPECT-derived measures of mechanical dyssynchrony have low intra-observer and inter-observer variabilities. (39)

Cardiac Resynchronization Therapy Symposium

As well as providing measures of mechanical dyssynchrony, SPECT also permits assessment of myocardial perfusion and myocardial viability, factors which are known to be important in the response to CRT. (14,15,40,41). In a study of 20 patients, Sciagra et al showed that, compared with patients with no perfusion defects, patients with perfusion defects affecting $\geq 50\%$ of the myocardial wall on SPECT had a worse quality of life and six-minute walking distance 3 months after CRT device implantation. (42). Whilst symptomatic benefit was observed in patients with and without perfusion defects, those with perfusion defects did not exhibit reverse LV remodelling. In a study of 51 patients with heart failure due to ischaemic cardiomyopathy, Ypenburg et al also showed a relationship between the response to CRT and the extent of viable myocardium and scar tissue. Furthermore, up to the 29% with transmural scar tissue ($< 50\%$ tracer activity) in the region of the LV pacing lead showed no improvement after 6 months of CRT. (43) In a retrospective study of 51 patients, Adelstein et al. showed that a low myocardial perfusion score and the average scar density in the segments immediately adjacent to the LV lead were significantly lower response in responders versus non-responders to CRT (response defined as $\geq 15\%$ increase in LVEF). (44)

Nuclear imaging permits assessment of patients with poor echocardiographic windows.

Disadvantages, however, include a low spatial and temporal resolution and the use of radiation.

Computerised tomography

Contrast-enhanced ventriculography using currently available computed tomography (CT) allows adequate delineation of myocardial borders throughout the cardiac cycle, thus making it a potential imaging modality for the assessment of mechanical dyssynchrony. Truong et al studies 38 patients undergoing CRT using 64-slice CT. (45) Endocardial and epicardial borders were contoured throughout the cardiac cycle, with each cycle divided into 10 phases. The dyssynchrony index was defined as the standard deviation of the time to maximal wall thickness for each myocardial segment. The mean dyssynchrony index was 152 ± 44 ms for patients with heart failure and a wide QRS duration 65 ± 12 ms for age-matched controls. The authors found excellent agreement between the two independent observers. Whilst this dyssynchrony index has not been evaluated against the outcome of CRT, a good agreement with speckle tracking has been shown. (45)

Cardiovascular magnetic resonance

Cardiovascular magnetic resonance (CMR) has gained widespread acceptance as the gold standard investigation for the *in vivo* quantification of ventricular volumes. Recently, CMR has been applied to the assessment of mechanical dyssynchrony. As with other imaging modalities, dyssynchrony can be measured in terms of the temporal dispersion of myocardial motion. Chalil et

Cardiac Resynchronization Therapy Symposium

al have recently used the standard deviation of the time to peak wall motion in myocardial segments as a measure of dyssynchrony (**Fig. 2**). (46) Compared with tissue Doppler measures of dyssynchrony, the so-called CMR tissue synchronisation index (CMR-TSI) emerged as a good discriminator between healthy controls and patients with heart failure **Fig. 3**). Furthermore, the CMR-TSI was identified as a powerful independent predictor of morbidity and mortality after CRT: patients with a CMR-TSI ≥ 110 ms were 3.8 times more likely to die from cardiovascular causes, compared with patients with a CMR-TSI < 110 ms. These findings support the use of dyssynchrony assessment using CMR in the risk-stratification of patients undergoing CRT.

Figure 2




Figure 2: Assessing dyssynchrony using wall motion obtained using cardiovascular magnetic resonance. (a) shows the left ventricle sliced into slices from the base (top) to apex (bottom), with each slice consisting of 6 segments; (b) shows the left ventricle in short axis, with manual contouring of the left ventricular epicardial and endocardial borders; (c) shows wall motion plotted against time in a healthy control; (d) shows wall motion plotted against time in a patient with heart failure and a left bundle branch block (LBBB). Reproduced with permission from Chalil et al. (46)

Cardiac Resynchronization Therapy Symposium

Figure 3




Figure 3: Assessing dyssynchrony in heart failure vs controls. (a) The standard deviation of the time-to-peak velocity in 12 myocardial segments derived from tissue Doppler imaging in healthy controls and in patients with heart failure, with a QRS duration 120 ms and ≥ 120 ms. [reproduced with permission from Yu CM et al (23)]; (b) standard deviation of the time to peak inward wall motion (CMR-TSI) in healthy controls and in patients with heart failure with varying QRS durations. (reproduced with permission from Chalil et al (46). Note the lack of overlap in CMR-TSI between healthy controls and patients with heart failure.

Other CMR methods for assessing cardiac dyssynchrony have emerged. Myocardial tagging, which is the gold-standard technique for assessing myocardial motion, permits assessment of wall motion as well as strain in circumferential, radial and longitudinal directions. (47,48) (**Fig. 4**) Strain-coded CMR provides real-time quantitative strain measurement, which is applicable to a rapid assessment of LV dyssynchrony. (47) Helm et al have recently developed a method for assessing dyssynchrony using three-dimensional tagged CMR. (49) Velocity-encoded CMR has recently

Cardiac Resynchronization Therapy Symposium

been shown to have an excellent agreement with TDI. (50) Although useful experimentally, these techniques have not been validated against the clinical outcome of CRT. Their application in clinical practice is therefore limited.

Figure 4




Figure 4. Example of cardiovascular magnetic resonance tags superimposed on a short axis image of the left ventricle. The linear tags (low signal) label areas of the myocardium throughout the cardiac cycle. The lines appear 'stretched' during systole. Tracking of tagged myocardium using specialised software allows determination of wall motion and strain in longitudinal, circumferential and radial directions.

Endocardial mapping

At its simplest, QRS duration of the 12-lead ECG provides a crude measure of electrical dyssynchrony. The distribution of myocardial activation, however, is best studied using intracardiac techniques, such as endocardial mapping. Using this technique, Auricchio's group have shown that, in normal hearts, the sites of latest activation are the posterobasal and posterolateral segments. (51) In patients with heart failure and a left bundle branch block (LBBB), ventricular

Cardiac Resynchronization Therapy Symposium

activation follows an U-shaped pattern, turning around the apex and inferior wall before it reaches the posterolateral segments. (51) The pattern of ventricular activation in LBBB is highly variable, (52) but the response to CRT appears to be greatest in patients with evidence of conduction block, rather than in patients with homogenous activation. (53)

By identifying the zone of latest activation, non-contact mapping also provides information about the best site for LV lead deployment. (54) Lambiase et al studied 10 patients with heart failure with endocardial mapping. (55) They hypothesised that failure to respond to CRT results from pacing areas of slow conduction, whereas deploying the lead in a site of normal activation results in an improved haemodynamic response. In this acute study, patients underwent non-contact mapping during intrinsic sinus rhythm and during paced rhythm. A roving LV catheter was used to pace the LV during biventricular pacing. In patients with ischaemic cardiomyopathy, a zone of slow conduction was found around the coronary sinus, with a velocity 73% slower than the LV lateral free wall. Pacing the area of normal activation rather than a zone of slow conduction resulted in a 22% rise in maximum dP/dt, which represented a 15% increase in cardiac output. This study showed how non-contact mapping can be used to direct optimal LV lead deployment. A limitation of endocardial mapping studies is that the LV lead is normally in contact with the epicardium. It is uncertain whether the findings of endocardial mapping studies can be extrapolated to the epicardium.

Conclusions

Echocardiography is the most widely studied modality for the assessment of mechanical dyssynchrony. Whilst various measures of dyssynchrony have been proven to predict the outcome of CRT in single-centre studies, they have proven to be of limited clinical applicability in a large multicentre study. Further refinements in the echocardiographic techniques and their application to the selection of candidates for CRT are required. Other imaging techniques using CMR, radionuclide scintigraphy and CT have an evolving potential in the selection of patients for this therapy. Either alone or in combination with electrical mapping, such techniques can be used to derive global and regional measures of mechanical dyssynchrony, which may be useful in selecting patients for CRT as well as in guiding LV lead deployment. Adequate evaluation of these modalities against clinically meaningful endpoints is required before introducing them into the clinical arena.

REFERENCES

Cardiac Resynchronization Therapy Symposium

1. Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. *Pacing Clin Electrophysiol* 1994;17:1974-1979.
2. Leclercq C, Cazeau S, Le Breton H, et al. Acute hemodynamic effects of biventricular DDD pacing in patients with end stage heart failure. *J Am Coll Cardiol* 1998;32:1825-1831.
3. Auricchio A, Stellbrink C, Block M, et al. Effect of Pacing Chamber and Atrioventricular Delay on Acute Systolic Function of Paced Patients with Congestive Heart Failure. *Circulation* 1999;99:2993-3001.
4. Cazeau S, Leclercq C, Lavergne T, et al. The Multisite Stimulation in Cardiomyopathies Study I. Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay. *N Engl J Med* 2001;344:873-880.
5. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, on behalf of the CArdiac RecynchronizatiOn in Heart Failure (CARE-HF) Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005; 352:1539-1549.
6. Bristow MR, Saxon LA, Borehmer J, et al. for the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced heart failure. *N Eng J Med* 2004;350:2140-2150.
7. Atherton JJ, Moore TD, Lele SS, et al. Diastolic ventricular interaction in chronic heart failure. *The Lancet* 1997;349:1720-1724.
8. Bleasdale RA, Turner MS, Mumford CE, et al. Left ventricular pacing minimizes diastolic ventricular interaction, allowing improved preload-dependent systolic performance. *Circulation* 2004;110:2395-2400.
9. Ypenburg C, Lancellotti P, Tops LF, Bleeker GB, et al. Acute Effects of Initiation and Withdrawal of Cardiac Resynchronization Therapy on Papillary Muscle Dyssynchrony and Mitral Regurgitation. *J Am Coll Cardiol* 2007;50:2071-2077.
10. Nunez A, Alberca MT, Francisco G, et al. Severe mitral regurgitation with right ventricular pacing, successfully treated with left ventricular pacing. *Pacing Clin Electrophysiol* 2002; 25:226-230.

Cardiac Resynchronization Therapy Symposium

11. Roba M, Anguera I, Champagne J, et al. Left ventricular pacing reduces systolic mitral regurgitation and improves mitral valve closure in heart failure patients with markedly prolonged QRS. *Eur Heart J* 2000;21:119.
12. Lindner O, Vogt J, Kammeier A, et al. Effect of cardiac resynchronization therapy on global and regional oxygen consumption and myocardial blood flow in patients with non-ischaemic and ischaemic cardiomyopathy. *Eur Heart J* 2005; 26:70-76.
13. Wikstrom G, Lundqvist CB, Andren B, et al, on behalf of the CARE-HF Investigators. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. *Eur Heart J* 2009;Epub ahead of print.
14. Chalil S, Foley PWX, Muihaldeen SA, et al. Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. *Europace* 2007; 9:1031-1037.
15. Chalil S, Stegemann B, Muihaldeen S, Khadjooi K, Foley PWX, Smith REA, Leyva F. Effect of posterolateral left ventricular scar on mortality and morbidity following cardiac resynchronization therapy. *Pacing Clin Electrophysiol* 2007;30:1-9.
16. Khadjooi K, Foley P, Anthony J, Chalil S, Smith R, Frenneaux M, Leyva F. Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. *Heart* 2008;94:879-883.
17. Gasparini M, Auricchio A, Metra M, et al. on behalf of the Multicentre Longitudinal Observational Study (MILOS) Group. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of atrio-ventricular junction ablation in patients with permanent atrial fibrillation. *Eur Heart J* 2008;29:1644-1652.
18. Cleland JGF, Cullington D, Khaleva O, Tageldien A. Cardiac resynchronization therapy: dyssynchrony imaging from a heart failure perspective. *Curr Opin Cardiol* 2008; 23:634-645.
19. Yu CM, Bleeker GB, Fung JW, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. *Circulation* 2005; 112:1580-1586.

Cardiac Resynchronization Therapy Symposium

20. Yu CM, Fung WH, Lin H, Zhang Q, Sanderson JE, Lau CP. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. *Am J Cardiol* 2003; 91:684-688.
21. Bax JJ, Marwick TH, Molhoek SG, et al. Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation. *Am J Cardiol* 2003; 92:1238-1240.
22. Yu CM, Chan YS, Zhang Q, et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. *J Am Coll Cardiol* 2006; 48:2251-2257.
23. Yu CM, Lin H, Zhang Q, Sanderson JE. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. *Heart* 2003; 89:54-60.
24. Bax JJ, Abraham T, Barold SS, et al. Cardiac Resynchronization Therapy: Part 1--Issues Before Device Implantation. *J Am Coll Cardiol* 2005;46:2153-2167.
25. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. *J Am Coll Cardiol* 2004; 44:1834-1840.
26. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) Trial. *Circulation* 2008;117:2608-2616.
27. Yu CM, Bax JJ, Gorcsan III J. Critical appraisal of methods to assess mechanical dyssynchrony. *Curr Opin Cardiol* 2009;24:18-28.
28. Gorcsan III J, Abraham T, Agler DA, et al. Echocardiography for Cardiac Resynchronization Therapy: Recommendations for Performance and Reporting-A Report from the American Society of Echocardiography Dyssynchrony Writing Group Endorsed by the Heart Rhythm Society. *J Am Soc Echocardiogr* 2008; 21:191-213.
29. Marwick TH. Hype and Hope in the Use of Echocardiography for Selection for Cardiac Resynchronization Therapy: The Tower of Babel Revisited. *Circulation* 2008; 117:2573-2576.
30. Miyazaki C, Powell BD, Bruce CJ, et al. Comparison of Echocardiographic Dyssynchrony Assessment by Tissue Velocity and Strain Imaging in Subjects With or Without Systolic Dysfunction and With or Without Left Bundle-Branch Block. *Circulation* 2008; 117:2617-2625.

Cardiac Resynchronization Therapy Symposium

31. Van Bommel RJ, Delgado V, Ypenburg C, et al. Left Ventricular Dyssynchrony Measured by Speckle-Tracking Radial Strain Analysis Predicts Survival After Resynchronization Therapy. *Circulation* 2008;118:S8678 (abstract).
32. Soliman OII, Theuns DAMJ, Geleijnse ML, et al. Spectral pulsed-wave tissue Doppler imaging lateral-to-septal delay fails to predict clinical or echocardiographic outcome after cardiac resynchronization therapy. *Europace* 2007;9:113-118.
33. Conca C, Faletra FF, Miyazaki C, et al. Echocardiographic Parameters of Mechanical Synchrony in Healthy Individuals. *Am J Cardiol* 2009;103:136-142.
34. De Boeck BWL, Meine M, Leenders GE, et al. Practical and conceptual limitations of tissue Doppler imaging to predict reverse remodelling in cardiac resynchronisation therapy. *Eur J Heart Fail* 2008;10:281-290.
35. Marwick TH. Measurement of Strain and Strain Rate by Echocardiography: Ready for Prime Time?. *J Am Coll Cardiol* 2006;47:1313-1327.
36. Fauchier L, Marie O, Casset-Senon D, et al. Interventricular and intraventricular dyssynchrony in idiopathic dilated cardiomyopathy. A prognostic study with Fourier phase analysis of radionuclide angioscintigraphy. *J Am Coll Cardiol* 2002;40:2022-2030.
37. Henneman MM, Chen J, Ypenburg C, et al. Phase Analysis of Gated Myocardial Perfusion Single-Photon Emission Computed Tomography Compared With Tissue Doppler Imaging for the Assessment of Left Ventricular Dyssynchrony. *J Am Coll Cardiol* 2007; 49:1708-1714.
38. Henneman MM, Chen J, Dibbets-Schneider P, et al. Dyssynchrony as Assessed with Phase Analysis on Gated Myocardial Perfusion SPECT Predict Response to CRT?. *J Nucl Med* 2007; 48:1104-1111.
39. Trimble MA, Borges-Neto S, Honeycutt EF, et al. Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction. *J Nucl Cardiol* 2008;15:663-670.
40. Bleeker GB, Kaandorp TAM, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. *Circulation* 2006;113:969-976

Cardiac Resynchronization Therapy Symposium

41. White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. *J Am Coll Cardiol* 2006;48:1953-1960.
42. Sciagra R, Giaccardi M, Porciani MC, et al. Myocardial perfusion imaging using gated SPECT in heart failure patients undergoing cardiac resynchronization therapy. *J Nucl Med* 2004;45:164-168.
43. Ypenburg C, Schalij MJ, Bleeker GB, et al. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. *Eur Heart J* 2007;28:33-41.
44. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. *Am Heart J* 2007;153:105-112.
45. Truong QA, Singh JP, Cannon CP, et al. Quantitative Analysis of Intraventricular Dyssynchrony Using Wall Thickness by Multidetector Computed Tomography. *J Am Coll Cardiol Img* 2008; 1:772-781.
46. Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular Dyssynchrony Predicts Mortality and Morbidity After Cardiac Resynchronization Therapy: A Study Using Cardiovascular Magnetic Resonance Tissue Synchronization Imaging. *J Am Coll Cardiol* 2007;50:243-252.
47. Lardo AC, Abraham TP, Kass DA. Magnetic Resonance Imaging Assessment of Ventricular Dyssynchrony: Current and Emerging Concepts. *J Am Coll Cardiol* 2005;46:2223-2228.
48. Wyman BT, Hunter WC, Prinzen FW, et al. Mapping propagation of mechanical activation in the paced heart with MRI tagging. *Am J Physiol* 1999;276:H881-H891.
49. Helm RH, Lecquerq C, Faris Q, et al. Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: Implications for assessing cardiac resynchronization. *Circulation* 2005;111:2760-2767.
50. Westenberg JJM, Lamb H, van der Geest RJ, et al. Assessment of left ventricular dyssynchrony in patients with conduction delay and idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 2006;47:2042-2048.

Cardiac Resynchronization Therapy Symposium

51. Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. *Circulation* 2004;109:1133-1139.
52. Fung JWH, Yu CM, Yip G, et al. Variable left ventricular activation pattern in patients with heart failure and left bundle branch block. *Heart* 2004;90:17-19.
53. Fung JWH, Chan JYS, Yip GWK, et al. Effect of left ventricular endocardial activation pattern on echocardiographic and clinical response to cardiac resynchronization therapy. *Heart* 2007;93:432-437.
54. Schilling RJ. Non-contact mapping of the left ventricle and new insights into the mechanisms for success of biventricular pacing. *Heart* 2004;90:3-4.
55. Lambiase PD, Rinaldi A, Hauck J, et al. Non-contact left ventricular endocardial mapping in cardiac resynchronisation therapy. *Heart* 2004;90:44-51.